Summit Corporation PLC : Total voting rights

Accessibility: Skip TopNav

July 23, 2013 08:00 ET

Summit Therapeutics plc

Summit Therapeutics plc

Summit Corporation plc

('Summit' or 'the Company')

Oxford, UK, 23 July 2013 - Summit (AIM: SUMM), a drug discovery and development company advancing therapies for Duchenne Muscular Dystrophy and C. difficile infection, announces that for the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 446,357,841 Ordinary shares of 1 pence each, with one voting right per share. There are no shares held in treasury.  The total number of voting rights in the Company is therefore 446,357,841.

The above figure of 446,357,841 shares may be used by shareholders as a denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company, under the Disclosure and Transparency Rules.

Summit is an Oxford, UK based drug discovery and development Company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection.  Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM. Further information is available at www.summitplc.com and follow Summit on Twitter (@summitplc).

For more information, please contact: